

AIM2CERV Phase III in Cervical Cancer

Axalimogene Filolisbac (AXAL)

ADVAXIS IMMUNOTHERAPIES™

High-risk, locally advanced cervical cancer

- FIGO stage I-II with positive pelvic nodes
- FIGO stage III-IV
- Any FIGO stage with para-aortic nodes

Total sites: 150 sites in 20 countries

GOG is supporting AIM2CERV by acting as a Site Management Organization

Trial timeline (predicted)

- First patient enrollment: 3Q16
- Last patient enrollment: 2Q18
- Final data readout: 3Q19



For more information, contact Kim Gilbert, Associate Director, Clinical Operations: gilbert@advaxis.com Phone: 609-250-7563

305 College Road East Princeton, NJ 08540 Phone: 609-452-9813 Fax: 609-452-9818



AIM2CERV Phase III in Cervical Cancer

Axalimogene Filolisbac (AXAL)

ADVAXIS IMMUNOTHERAPIES™

TRIAL PHASE	Phase III
STUDY CENTERS	Multicenter, global in 20 countries; 150 sites
TRIAL BLINDING	Double-blinded, placebo-controlled
NUMBER OF TRIAL PATIENTS	Approximately 450
ESTIMATED DURATION	Approximately 21 months for recruitment • 1 year of treatment • 3-5 years follow up
RANDOMIZATION RATIO	1:2 Arm A to Arm B
METHODOLOGY	This is a double-blind, placebo-controlled randomized study of AXAL administered in the adjuvant setting after completion of cisplatin-based CCRT in patients with locally advanced cervical cancer at higher risk for recurrence, progression, or death

OBJECTIVES	• Primary: Disease-free survival (DFS) • Secondary: Safety, tolerability, and overall survival
STATISTICAL CONSIDERATIONS	• 184 events provide 85% power for detecting a treatment hazard ratio of 0.620 • DFS will be defined as the time from randomization until death, progression, or first documented relapse, categorized as either locoregional (primary site or regional nodes) failure or distant metastasis • An interim analysis will be performed when there is at least one-half the number of DFS events required for full maturity of the study • Logrank test of the null hypothesis HP:E, DFS will be calculated and futility will be assessed
COUNTRIES	Argentina, Brazil, Canada, Chile, Hong Kong, Ireland, Korea, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, Serbia, Spain, Taiwan, UK, Ukraine, US

For more information, contact Kim Gilbert, Associate Director, Clinical Operations: gilbert@advaxis.com Phone: 609-250-7563

305 College Road East Princeton, NJ 08540 Phone: 609-452-9813 Fax: 609-452-9818